

Index

A

- ACE inhibitor-sensitized MR renography, 854–855
- Acquired cystic kidney disease (ACKD)
characteristics, 315, 316
renal cell carcinoma
development process, 316, 317
diagnosis, 316, 317
prevalence, 317
- Acute bacterial pyelonephritis. *See* Bacterial pyelonephritis
- Acute glomerulonephritis, 87, 88, 345, 740, 741
- Acute nephritic syndrome, 336
- Acute renal failure (ARF)
causes of, 723–724
clinical scenarios
cortical necrosis, 724, 725, 745
hemolytic uremic syndrome, 744
hepatorenal failure (HRF), 744
multiple myeloma, 746
renal intrinsic causes, 746
differential diagnosis, 741
elderly, 723–724, 741, 743, 744
GFR estimation, 740
pediatric kidney, 703
postrenal ARF
benign prostatic hypertrophy, 727, 745, 747
RIs values, 741
ultrasound (US), 740
prerenal and renal ARF
Doppler US, 724–726, 740–745
glomerulonephritis, 740, 741, 744, 745
hospitalized patients, 728, 741–742
morphological evaluation, 740–742
renal size, 741, 747, 750
RIs values, 742
tubular necrosis, 740, 741, 744
- Acute renal infections
bacterial pyelonephritis (*see* Bacterial pyelonephritis)
gas-forming renal infections (*see* Gas-forming renal infections)
renal and perinephric abscess
clinical features and pathophysiology, 429
imaging, 429–431
- Acute renal ischemia, 209
- Acute tubular necrosis (ATN), 87, 184, 185, 234, 240, 242, 249, 336, 345, 392, 393, 724, 740, 741, 744, 746, 771, 780, 781, 855, 872, 874, 875, 881
- ADPKD. *See* Autosomal dominant polycystic kidney disease (ADPKD)
- Advanced renal cell carcinoma, 195, 217–219
- Anastomosis
MR angiography, 3D contrast, 763
urinary obstruction, 765
vascular and ureterovesical, 759
- ANCA. *See* Antineutrophil cytoplasmic antibodies
- Aneurysms. *See* Renal artery aneurysms
- Angiomyolipoma (AML)
common renal lesions, 504
complicated angiomyolipomas
giant angiomyolipoma, 510, 512, 519, 521
hemorrhage, 516, 518, 519
left flank and abdominal pain, 520
fat signal lesions, 324
large angiomyolipoma (*see* Large angiomyolipoma)
MR imaging, 505
prevalence of, 504, 505
renal cysts and hyperechoic lesions, 323
small angiomyolipoma
computed tomography, 504–505
MR imaging, 505
unenhanced and contrast-enhanced US, 504, 506
T1-weighted image, 505, 507
- Angiosarcoma, 502, 636, 637
- Antidiuretic hormone (ADH), 23
- Antineutrophil cytoplasmic antibodies (ANCA), 337, 880
- Apparent coefficient diffusion (ADC)
necrotic/cystic components, 182
standardized values, 185
threshold values, 182
tumor and high viscosity fluids, 182
- ARF. *See* Acute renal failure (ARF)
- ARPKD. *See* Autosomal recessive polycystic kidney disease
- Arterial disease
renal artery stenosis (RAS)
clinical criteria, 471
CTA, 472
Doppler ultrasound, 471–474
fibromuscular dysplasia (FMD), 471, 472, 474
middle aortic syndrome, 471, 474–475
MRA techniques, 472–475
neurofibromatosis, 471, 474
Takayasu's disease, 471, 474, 475
renovascular hypertension, 471, 472
- Arterial thrombosis, 217, 477, 767
- Arteriovenous malformations, 31, 124, 137, 478, 497, 528, 533, 807
- Atheroembolic renal disease
clinical manifestation, 721
color and power Doppler US, 721
contrast-enhanced CT, 721
renal artery embolization, 721
renal failure, 721
- Atherosclerosis, 45, 103, 105, 183, 184, 201, 397, 471, 477, 710, 715, 718, 719, 723, 788, 789, 872
- Atherosclerotic renal artery, 183, 202–205, 207
- ATN. *See* Acute tubular necrosis (ATN)

- Atypical angiomyolipomas
 hemostatic agents, 512, 516
 renal angiomyolipoma vs. fatty packing material, 512
- Autosomal dominant polycystic kidney disease (ADPKD), 287, 290, 292, 306–308, 315–321, 323, 479, 753
- Autosomal recessive polycystic kidney disease (ARPKD), 87, 88, 287–292, 306–308, 317, 321–322
- Avascular renal cell carcinoma, 553, 554
- Average intensity projections (AIP), 155, 156, 357
- B**
- Bacterial pyelonephritis
 complicated infection, 412
 computed tomography
 bilateral and multifocal acute bacterial pyelonephritis, 418, 420
 differential enhancement pattern, 416
 diffuse pyelonephritis, 420
 drug abuse, clinical signs of, 420
 focal hypoattenuating areas, 418
 helical and multidetector CT, 416
 multifocal hematogenous pyelonephritis, 418, 420
 parenchymal volume reduction, 418, 419
 postcontrast coronal multiplanar reconstruction, 417
 pyelitis and focal acute pyelonephritis, 422
 secondary signs, 418
 soft tissue filling defect, 420
 unenhanced CT, 416
 definitions, 411–412
 diabetic patients, 412
 infection route
 ascending route, 412
 hematogenous route, 413
 lymphatic route, 413–414
 intravenous urography, 414
 laboratory findings, 412
 magnetic resonance imaging
 conventional MRI findings, 424
 diffusion-weighted (DW) imaging, 428
 gadolinium-enhanced inversion recovery, 424, 426, 427
 renal MRI, 423–424
 static-fluid MR urography, 427
 nuclear medicine, 414
 pathogens, 412, 413
 ultrasound (US)
 acute focal pyelonephritis, 415
 contrast-enhanced ultrasonography, 415
 Doppler US, 415
 fungal infection, 415
 uncomplicated infection, 414
- Benign solid renal tumors
 angiomyolipomas (*see* Angiomyolipoma)
 arteriovenous malformations, 528, 533, 534
 clinical management, 503
 embryonal metanephric adenoma, 526
 incidence, 503
 malignant renal tumors and, 503
 MR imaging, 502, 503
 neoplasms (*see* Renal cell neoplasm)
 phakomatoses, 526–528
- Bilateral angiomyolipomas, 511
- Bilateral renal agenesis, 36, 285
- Birt–Hogg–Dubé syndrome (BHD), 523, 554–555, 664
- Bladder carcinoma
 azotemia, 374
 postrenal acute renal failure, 374
- Blood urea nitrogen (BUN), 25, 26
- Bosniak classification system, 645, 651, 654–664
 category IIF lesions, 654, 655, 657, 660, 661
 category III lesions, 654, 655, 657, 660, 662–664
 category II lesions, 654, 657–659, 664
 category I lesions, 654, 656–658
 category IV lesions, 654, 655, 657, 660, 663
 cystic renal masses, 654–656
 field of application, 655
 utility and limitations of, 661–664
- Bright’s disease, 248
- BUN. *See* Blood urea nitrogen
- C**
- Cadaveric donor kidneys evaluation, 758
- CAKUT. *See* Congenital abnormalities of the kidney and urinary tract (CAKUT)
- Calcium oxalate stones, 397, 398, 406
- Calculus disease, 395–397, 399, 406, 567, 782
- Calyceal diverticulum, 62, 67, 349, 362, 403, 406, 651, 655
- Calyceal stones, 271, 272
- CAN. *See* Chronic allograft nephropathy (CAN)
- Castleman disease, 575–576
- Catastrophic renal parenchymal injury
 bleeding, 486, 487, 489, 493, 494
 collecting system injury, 488, 492–495
 vascular injury, 489, 491, 493, 494
- Catheters, dialysis, 803–805
- Cell receptors, MR imaging, 879
- CEUS. *See* Contrast-enhanced ultrasound
- Charge-coupled device (CCD), 192
- Childhood renal trauma, 703–704
- Childhood urinary tract infection
 magnetic resonance imaging, 685
 Tc^{99m} DMSA scintigraphy, 685–686
 ultrasound (US)
 acute pyelonephritis, 383, 384, 386
 chronic xanthogranulomatous pyelonephritis, 685
 fungus ball, 685
 necrosis and abscess formation, 684
 pyonephrosis, 684, 686
 upper urinary tract infection, 683, 684, 686
 vesicoureteral reflux, 683, 686
- Chloromas, 575, 638
- Cholesteatoma, 363, 368, 451, 464
- Cholesterinic renal embolization, 724, 725
- Chondrosarcoma, 636, 638
- Chromophobe carcinoma, 554
- Chronic allograft nephropathy (CAN), 240, 250, 757, 780–782
- Chronic glomerulonephritis, 88, 392, 393, 693
- Chronic kidney injury, 250
- Chronic lithium nephropathy, 329–330
- Chronic pyelonephritis, 88, 182, 345, 393, 412, 437–439, 445, 448, 567, 581, 685
- Chronic renal failure
 causes, 726, 750
 classification
 color Doppler US, 726–727, 751, 752
 GFR value, 726
 Gray-scale US, 728
 polycystic kidney disease, 747, 750, 751
 renal dialysis, 752, 753
 renal vascularization, 751, 752
 severity stages, GFR value, 750
 clinical scenarios
 ACE inhibitors, 726, 743–744

- Doppler US examination, 745
- HIV, 746, 754
- diabetes and hypertension, 747
- renal size reduction, 747, 750
- Chronic renal insufficiency (CRI), 412, 757, 782, 789, 811
- Clear cell RCC
 - angiography, 548
 - computed tomography
 - corticomedullary images, 541, 542
 - data acquisition time, 541
 - excretory phase, 542, 544
 - nephrographic phase, 542, 544
 - renal mass protocol, 542
 - vasculature and collecting system, 541
 - intravenous urography (IVU), 539
 - magnetic resonance imaging
 - breath hold sequences, 543
 - coronal subtracted MIP image, 544
 - cystic neoplasms, 544
 - hypointense lesion, 544, 546, 547, 549
 - T1-weighted gradient-recalled-echo (GRE), 544
 - plain radiographs, 539
 - positron emission tomography, 548
 - ultrasound, 539–541
- Complex cysts, 138, 307, 308, 310–311, 316, 318, 320, 430, 650, 655, 656, 659, 666–668, 798
- Complicated angiomyolipomas. *See* Angiomyolipoma
- Computed tomography (CT)
 - artifacts, 127–129
 - contrast-enhanced CT, 131–144
 - cortical (rim) nephrogram, 147, 149
 - CT angiography, 160
 - delayed CT nephrogram, 144
 - detector configuration, 126, 130, 136, 157
 - dual-energy CT, 160–163
 - imaging, 125–127
 - multidetector CT urography, 149–160
 - patient preparation, 132
 - radiation dose, 129–131
 - unenhanced CT, 132–134
- Computed tomography angiography (CTA), 42, 45–51, 126, 160, 190, 212, 469, 470, 472, 474, 475, 477, 478, 480, 694, 697, 718–720, 723, 758
- Congenital abnormalities of the kidney and urinary tract (CAKUT), 4, 12–14
- Congenital and development disorders
 - ADPKD, 290, 292
 - ARPKD, 288, 289
 - congenital renal tumours, 299
 - crossed fused ectopia, 285
 - cystic renal dysplasia, 287, 288
 - duplex kidney, 295
 - ectopic kidney, 283–284
 - embryology, 283
 - GCKD, 292
 - horseshoe kidneys, 284–285
 - MCDC, 292
 - multicystic dysplastic kidney, 287
 - posterior urethral valves, 291, 295–297
 - prune belly syndrome, 297
 - renal agenesis, 285
 - renal hypoplasia, 285–287
 - renal pelvis and ureter dilatation, 294–295
- Congenital hydronephrosis, 362, 687–691
- Contrast-enhanced computed tomography
 - PCNL, 151
 - renal masses, 150
 - renal traumas, 141, 143
 - transverse images, 137, 142, 154
- Contrast-enhanced magnetic resonance renography, 172, 184–186, 202, 544
- Contrast-enhanced ultrasound (CEUS)
 - additional imaging, 114
 - Bosniak classification, 118–119
 - contrast enhancement, 114–118
 - cystic renal tumors, 115
 - intratumoral septa, 115, 118
 - microbubble contrast agents, 113–119
 - noninvasive quantization, 114
 - percutaneous ablation, 90
 - pharmacologic treatment, 114
 - reference technique, 119
 - renal perfusion defect, 113–115
 - solid renal tumor, 115–117
 - sulfur hexafluoride microbubble, 116–118
 - tissue enhancement, 113
 - tumoral vessels, 117
- Contrast media-induced nephropathy (CIN)
 - clinical features, 826–827
 - definition, 826
 - guidelines, 830
 - incidence, 826
 - risk factors
 - multiple risk factors, 828
 - patient-related, 827
 - procedure-related, 828
 - risk reduction strategies
 - contrast material, type and dose, 828
 - hemodialysis and hemofiltration, 829
 - hydration, 829
 - pharmacologic agents, 829
 - physiologic variations, 830
- Contrast pulse sequencing (CPS), 110, 111, 116–118
- Cortical nephrocalcinosis
 - bilateral uniform cortical nephrocalcinosis, 393
 - chronic glomerulonephritis, 392, 393
 - pathologic conditions, 392
- Cortical (rim) nephrogram, 147, 149
- CPS. *See* Contrast pulse sequencing (CPS)
- CRI. *See* Chronic renal insufficiency (CRI)
- Crossed fused ectopia, 42, 43, 285, 286, 288
- Cryoablation. *See also* Radiofrequency ablation
 - complications, 599, 600
 - outcomes, 598, 599
 - procedure, 595–597
 - vs. radiofrequency ablation, 595
- CTA. *See* Computed tomography angiography (CTA)
- Cystic lesions, 90, 91, 115, 119, 124, 128, 129, 140, 146, 168, 171, 172, 182, 306, 310, 311, 325, 567, 577, 583, 621, 645, 646, 651, 652, 654–656, 658, 660, 662, 663, 666, 669, 728, 817
- Cystic renal dysplasia, 287, 288, 291
- Cystic renal masses
 - benign cystic neoplasms
 - anatomy, 647
 - mixed epithelial and stromal tumors, 646
 - multilocular cystic nephromas, 646, 647
 - renal epithelial and stromal tumors, 646
 - Bosniak classification system (*see* Bosniak classification system)
 - computed tomography, 645, 650–652
 - contrast-enhanced ultrasound, 650, 651

- Cystic renal masses (*cont.*)
 conventional ultrasound, 649–650
 definition, 646
 indeterminate and misclassified cysts
 discrepant findings, 667–670
 indeterminate attenuation, 664–667
 indeterminate enhancement, 667
 very small renal masses, 664
 malignant cystic neoplasms
 clear cell/papillary RCCs, 648
 multilocular cystic RCC, 648
 tubulocystic carcinoma, 649
 MR imaging, 652–654
 Cystine stones, 365, 397
- D**
 DECT. *See* Dual-energy computed tomography
 Diabetic nephropathy, 250, 336, 340–341, 726, 741, 750, 855, 879
 Dialysis access complications, uremia
 arteriovenous fistula, 798–800
 arteriovenous grafts, 800–803
 catheters, 803–805
 vascular stenoses, 798
 Diffusion tensor imaging (DTI), 857, 858
 Digital subtraction angiography (DSA)
 digital fluoroscopy/fluorography, 190
 intra-stent restenosis, 195
 processing options, 192
 Direct radionuclide cystography (DRC)
 bladder catheterization, 229
 low-grade refluxes, 238
 Distal renal tubular acidosis, 88, 393, 394, 396, 692
 Distant metastases
 metachronous, 821–822
 postoperative imaging surveillance, 822
 Diuretic scintigraphy, 228–229, 235–238
 Doppler technique
 parenchyma vascularity, 99–100
 renal parenchyma vessels, 102
 renal tumors, 100
 renal vasculature, 97
 renal vessels, 100–105
 Drug nephropathies, 88, 345
 Dual-energy computed tomography (DECT)
 renal lesions, 163
 renal masses, 163
 Duplex Doppler sonography, 105, 355, 401
 Duplex kidney, 295, 423, 689
 Dynamic renal scintigraphy, 227–229
- E**
 Ectopic kidney, 12, 39, 42, 43, 283–285
 Ectopic ureter, 12, 57
 Effective renal plasma flow (ERPF), 225, 226, 229, 242
 Embryology
 apoptosis, 11–12
 ectopic kidney, 12
 ectopic ureter, 12
 fused/horseshoe kidney, 12
 hypoplastic kidney, 12
 inductive processes and proliferation, 10, 11
 lobes, 9–10
 metanephros/ permanent kidney, 6–9
 migration, 9
 pronephros, 6
 supernumerary renal arteries, 10
 urinary tract duplications, 12–14
 urogenital system, 4–5
 vascular variations, 10
 wilms tumor, 14
 Embryonal metanephric adenoma, 526, 528, 529
 Emphysematous pyelonephritis
 clinical presentation, 433
 computed tomography, 434
 diabetes, 433
 medical management, 433
 non-diabetes, 433
 ultrasound (US) evaluation, 433
 X-ray, 433
 Endovascular interventions, 190, 195–197, 717
 End-stage renal disease (ESRD), 183, 249, 315, 317, 318, 321, 340, 342, 376, 392, 564, 584, 726, 747, 788, 789, 792, 798, 882
 Erdheim–Chester disease, 586–587
 ERPF. *See* Effective renal plasma flow (ERPF)
 ESRD. *See* End-stage renal disease (ESRD)
 ESWL. *See* Extracorporeal shock wave lithotripsy (ESWL)
 Evaluation of medical products (EMEA), 108
 Ewing sarcoma and primitive neuroectodermal tumor (ES-PNET), 638
 Extra-adrenal myelolipoma, 578
 Extracorporeal shock wave lithotripsy (ESWL), 132, 143, 148, 216, 395, 402, 406, 584, 585
 Extraparenchymal renal sinus cysts, 312–315
- F**
 Familial renal oncocytoma, 554–556
 Fascia transversalis, 75, 79
 Fibromuscular dysplasia (FMD)
 causes, 184, 207, 471, 472, 715
 endovascular treatment, 207–208
 variants and angiography, 205–207
 Fibrosarcoma, 636, 637, 697
 Fibrous septa, 29, 79, 87, 646
 Fistulas
 dialysis access, 798
 transplantation, 151
 Fluoroscopy, 190, 192, 262–264, 267, 268, 271, 273, 277, 676, 678, 682, 687
 FMD. *See* Fibromuscular dysplasia (FMD)
 Focal glomerulosclerosis, 336, 337, 475, 710
 Functional imaging method
 ACE inhibitor-sensitized MR, 854–855
 renography, 854–855
 contrast agents and technical issues
 CT, 840
 MRI, 840–841
 sonography, 840
 diffusion, 840, 855–858
 glomerular filtration rate (GFR) measurement
 indications, 841
 MR quantification, 842–843
 split renal function, 841–842
 intrarenal oxygenation, 855
 perfusion
 MRI, 848–851
 ultrasound, 848
 renal blood flow (RBF) rate, 847
 tubular function, 851–854
 urinary excretion and renal transit time, 854

Fungal infections

- Aspergillus*, 452
- Candida albicans*
 - acute pyelonephritis, 453, 465
 - immunocompromised patient, 452, 466
- cryptococcosis, 453

Fused/horseshoe kidney, 12

G

Gas-forming renal infections

- emphysematous pyelitis, 434–435
- emphysematous pyelonephritis
 - clinical presentation, 433
 - computed tomography, 434
 - diabetes, 433
 - medical management, 433
 - non-diabetes, 433
 - ultrasound (US) evaluation, 433
 - X-ray, 433

Gastrointestinal stromal tumor (GIST), 579

GBM. *See* Glomerular basement membrane (GBM)GCKD. *See* Glomerulocystic kidney disease (GCKD)

Gene therapy, MR imaging, 878–879

Genitourinary tuberculosis

- caseified tissue necrosis, 443
- closed form, 443, 454, 455
- contrast-enhanced CT
 - excretory phase, 449, 452–455, 460, 465
 - nephrographic phase, 431, 434, 446, 458, 462, 465
- CT urography
 - coronal reformation, 349, 406, 407, 439, 448, 464
 - infundibulum and phantom calyx, 443
 - renal calcifications, 440
- diffuse cavitating open form, 449
- intravenous excretory urography
 - calyceal distortion, 438–440, 464
 - tubercular stricture, 442, 443
- morphologic alterations, parenchyma, 440
- Mycobacterium tuberculosis*, 439, 440, 452
- open form, 446, 447, 449, 452, 453
- putty kidney, 445, 456, 457
- scheme, 454, 456
- ultrasound scan, 444
- xanthogranulomatous pyelonephritis (*see* Xanthogranulomatous pyelonephritis)

Geriatric kidney

- acute renal failure
 - acute cortical necrosis, 724, 725
 - cholesterinic renal embolization, 724, 725
 - hypertensive nephrosclerosis, 724
 - pathologies, 723, 724
 - renal artery stenosis, 724
- atheroembolic renal disease
 - clinical manifestation, 721
 - color and power Doppler US, 721
 - contrast-enhanced CT, 721
 - renal artery embolization, 721
 - renal failure, 721
- chronic renal failure, 726–727
- morphologic alterations, 710–711
- neoplastic pathologies
 - clear cell type, 730
 - lymphoma, 731
 - small renal tumor, 730
 - transitional cell carcinomas, 730

nephrosclerosis, 711–715

obstructive uropathy, 727–728

renal infarction

- capsular base, 719
- causes of, 719
- contrast-enhanced CT, 720
- Doppler US and power Doppler US, 719
- microbubble-based contrast agents, 719
- renal infections, 729 (*see also* Pyelonephritis)
- renal vein thrombosis, 721–723
 - causes, 721
 - contrast-enhanced CT, 722, 723
 - diagnosis, 723
 - pulmonary emboli, 723
 - unenhanced CT, 724

renovascular disease

- cardiopulmonary diseases, 717
- clinical manifestation, 721
- contrast-enhanced CTA, 722
- MR imaging angiography (MRA), 719
- renal artery stenosis, 724
- tardus-parvus phenomenon, 719

Gerota's fascia, 30, 77, 179, 341, 413, 418, 429, 433, 445, 448, 458, 459, 485, 557, 581, 635, 639, 809, 821

GFR. *See* Glomerular filtration rate (GFR)

Giant angiomyolipoma, 144, 510, 512, 519, 521

Giant fibroepithelial polyp, 628

GIST. *See* Gastrointestinal stromal tumor (GIST)

Glomerular basement membrane (GBM), 7, 249, 336, 340, 341, 710

Glomerular filtration rate (GFR)

- BUN, 25, 26
- creatinine clearance rate, 25–27
- indications, 27
- k*-constant value, 27
- MR quantification
 - global GFR, 27
 - single kidney extraction fraction, 847
 - single kidney GFR (SKGFR), 843–847
- split renal function, 841–842

Glomerulocystic kidney disease (GCKD), 287, 292, 306, 702

Glomerulonephritis

- acute, 87, 88, 345, 740, 741
- chronic, 88, 392, 393, 693

Glycogenosis, 343

Glycogen storage disease, 88, 393, 398

Gonadal vein thrombosis, 479

Goodpasture's syndrome, 249, 336, 872, 874

Grafts

- long-term follow-up, 780–782
- medical complications, 771–780
- preservation, 758–759
- radiological assessment
 - color Doppler, 766
 - MRI, 766
- urological complications, 760–762
- vascular complications, 767–771

Granulocytic sarcomas (chloromas), 575, 638–639

Gray-scale ultrasound

- anatomy, 534
- renal anatomy, 17–23
- renal echogenicity, 693
- solid and cystic renal tumors, 90–92

H

Half-Fourier single-shot technique (HASTE), 32, 56, 168, 360, 361

Hemangioblastoma, 304, 323, 554

Hemangioma, 181, 502, 527, 528, 531, 559, 577, 623, 698

- Hemangiopericytoma, 502, 636, 637
- Hematomas
renal injury, 584
renal pseudotumor, 577
subcapsular, 486–487
- Hematuria
CT urography, microscopic hematuria
asymptomatic, 158
MDCT, 158
sensitivity and specificity, 158
symptomatic, 158
diagnostic algorithm, 158
MDCT urography, 158
MR imaging, 158
- Hemodialysis, contrast media-induced nephropathy, 826–830
- Hemodynamic abnormalities, 340
- Hemofiltration, contrast media-induced nephropathy, 829
- Hemolytic uremic syndrome, 29, 249, 345, 693–695, 703, 744
- Hemorrhagic renal cyst, 93, 95, 135, 147, 794
- Hepatorenal syndrome, 749
- Hereditary leiomyoma renal cell carcinoma (HLRCC), 554
- Hereditary papillary renal cancer (HPRC), 554
- Hereditary renal carcinoma
Birt–Hogg–Dubé syndrome, 554–555
familial renal oncocytoma, 555–556
leiomyoma renal cell carcinoma, 554
papillary renal cancer, 554
tuberous sclerosis, 556
von Hippel–Lindau disease
coronal T-weighted MRI, 555
magnetic resonance imaging, 555
multilocular cystic and solid RCC, 555
pre- and postcontrast CT imaging, 555
ultrasound, 555
- HIV-associated nephropathy, 344–345
- HLRCC. *See* Hereditary leiomyoma renal cell carcinoma (HLRCC)
- Horseshoe kidneys, 12, 42–44, 199, 200, 229, 230, 284–285, 363, 369, 397, 579
- HPRC. *See* Hereditary papillary renal cancer (HPRC)
- Hydatid cyst, 582–583, 646, 655
- Hydration, 28, 29, 85, 132, 151, 153, 236, 237, 361, 478, 688, 689, 726, 740, 827–830, 851
- Hydronephrosis, 10, 67, 105, 132, 175, 232, 251, 262, 285, 308, 354, 394, 423, 440, 495, 539, 581, 605, 633, 680, 727, 742, 811, 850, 872
- Hyperchloremic metabolic acidosis, 336
- Hyperdense renal cyst, 141, 310, 659
- Hyperparathyroidism, 88, 345, 392–394, 396, 397, 692, 782, 789, 790
- Hypertension, 45, 108, 137, 181, 193, 238, 249, 265, 287, 307, 335, 354, 395, 438, 470, 497, 526, 577, 686, 710, 747, 769, 787, 808, 827, 855
- Hypertrophied column of Bertin, 34, 35, 38, 39, 588
- Hypervitaminosis D, 88, 393, 394
- Hypoplastic kidney, 12, 286
- Hypovascular renal cell carcinoma, 140
- I**
- Idiopathic nephrotic syndrome, 249, 721
- Iliac fascia, 78
- Indinavir calculi, 78
- Infarctions, 98, 149, 184, 204, 219, 475, 477, 527, 565, 704, 710, 712, 719, 720, 766, 773, 778, 789, 827, 865. *See also* Renal infarction
- Infarcts, 24, 207, 209, 346, 416, 418, 452, 475, 476, 486, 491, 548, 633, 711, 713, 714, 719, 720, 725, 761, 767, 817
- Infective calculi, 397
- Inflammatory disease. *See* Renal parenchymal and inflammatory diseases
- Insonation power, 109
- Intrarenal arterial disease
aneurysms, 477–478
arterial thrombosis, 477
embolism and infarction, 476–477
intravenous drug abuse, 475
polyarteritis nodosa (PAN), 475
radiation nephritis, 476
scleroderma, 475–476
systemic lupus erythematosus (SLE), 475
Wegener’s granulomatosis, 47
- Intrarenal fibrosis, MR imaging, 882–885
- Intrarenal oxygenation, 855
- Intrarenal vasculature
anatomical variants, 34–36
computed tomography, 30–31
conventional radiography, 28
gray-scale and Doppler ultrasound, 28–30
magnetic resonance imaging, 31–34
morphology, 34–36
- Intravenous excretory urography
calyceal deformities, 60
CTU, 60–63
- J**
- Juxtaglomerular cell tumors, 181, 577, 697
- K**
- Kaposi sarcoma, 576, 639
- Kidney development
apoptosis, 11–12
inductive processes and proliferation, 10–11
- Kidney in elderly patient. *See* Geriatric kidney
- Kidney–ureter–bladder (KUB), 28, 56, 157, 398, 399, 401, 402, 406, 539, 676, 677, 692
- L**
- LAO. *See* Left anterior oblique (LAO)
- Large angiomyolipoma
computed tomography
bilateral angiomyolipomas, 511
fat component, 511
giant angiomyolipoma, 512
gadolinium, contrast enhancement, 512
MR imaging
india ink artifact, 514
in-phase MR images, 505
opposed-phase chemical shift MRI, 505
out-of-phase MR images, 507
T- and T-weighted sequences, 507
- Large cell lymphoma, 633, 634
- Leadbetter–Politano technique, 759
- Left anterior oblique (LAO), 191, 192
- Leiomyosarcoma, 502, 554, 576, 590, 636–638
- Leukemia, 336, 345, 346, 502, 575–576, 586, 588, 634, 638, 696, 702
- Lich–Gregoir technique, 759
- Liposarcoma, 28, 181, 508, 577, 580, 588, 631, 636–638, 643
- Localized cystic disease, 182, 307, 308, 315, 316, 655, 656

- Lupus systemic erythematosus, 250, 342–343, 469, 475, 485, 586, 695, 719, 740
- Lymphoma. *See also* Renal lymphoma
 childhood, 180
 elderly, 180
- Lymphoproliferative disorders, 576, 584, 634, 783
- M**
- Macrophage imaging method
 intrarenal activity, 872
 principles, 872
 targeting methods
 experimental models, 872–875
 in humans, 875–878
- Magnetic resonance imaging (MRI)
 angiomyolipoma, 181
 benign renal masses, 181
 BOLD MRI, 185–186
 breath holding, 168
 cell receptors, 879
 contrast-enhanced magnetic resonance renography, 184–185
 cystic lesions, 182
 diffusion MRI and renal function, 185
 enzyme activity, 879
 equipment, 167–168
 gene therapy, 878–879
 intrarenal fibrosis, 882–885
 lymphoma, 179–180
 macrophage imaging method
 intrarenal activity, 872
 principles, 872
 targeting methods, 872–878
 magnetic resonance angiography, 17
 metastasis, 181
 oncocytoma, 181
 patient positioning, 168
 renal anatomy, 160
 renal artery stenosis, 183–184
 renal cell carcinoma, 176–179
 renal function, 185
 renal infections, 182–183
 renal transplant, 184
 sequences, 168–176
 urothelial carcinoma, 179
 USPIO particles, 186
- Magnetic resonance quantification, glomerular filtration rate
 global GFR, 842–843
 single kidney extraction fraction, 847
 single kidney GFR (SKGFR), 843–847
- Malacoplakia
 computed tomography, 451
 IVU, 539
 multifocal form, 583
 ultrasound (US), 451
 unifocal form, 450
- Malignant fibrous histiocytoma, 502, 553, 636–638
- Malignant lesions, 182, 219, 568, 623, 660, 662, 698
- Malignant tumors, 90, 138, 190, 217–219, 254, 323, 363, 367, 502, 503, 576, 584, 587, 603, 604, 622–623, 636, 638, 699–702, 730, 811
- Matrix calculi, 398, 403
- Matrix metalloproteinases (MMP), MR imaging, 879
- Maximum intensity projection (MIP)
 coronal images, 125
 reconstruction algorithm, 125
 urinary tract, 125
- MCDC. *See* Medullary cystic disease (MCDC)
- MCDK. *See* Multicystic dysplastic kidney (MCDK)
- MDCTU. *See* Multidetector CT urography (MDCTU)
- MDRD. *See* Modification of Diet in Renal Disease Study Group (MDRD)
- Medullary cystic disease (MCDC), 287, 292, 306
- Medullary hyperechogenicity, 88
- Medullary nephrocalcinosis
 analgesic nephropathy, 393, 394
 hypercalcaemic/hypercalciuric states, 394
 pyramidal calcification, 394
 renal tubular diseases, 394
 sponge kidney, 394
- Medullary renal cell carcinoma, 575
- Medullary sponge kidney (MSK), 68, 88, 89, 305–308, 323–325, 345, 392–395, 692, 702
- Medullary tumors
 collecting duct carcinomas (CDC)
 general features and pathogenesis, 573–574
 imaging features and differential diagnosis, 574–575
 renal medullary carcinoma, 575
- Mesenchymal tumors. *See also* Hemangioma
 lipoma, 576–577
 lymphangioma, 577
 renal leiomyomas, 576
- Mesoblastic nephroma, 279, 578, 696–698
- MEST. *See* Mixed epithelial and stromal tumors (MEST)
- Metanephros/permanent kidney, 5–8
- Metastasis, 181, 186, 243, 363, 369, 509, 523, 553, 557, 559, 562, 571, 572, 575, 621, 638, 640, 692, 696, 697, 700, 701, 734, 735, 808, 822, 879
- Microbubble contrast-specific techniques
 artifacts, 107
 chemical composition, 107–108
 clinical applications, 107
 dynamic phases, 112
 insonation power, 109
 safety, 108–109
 ultrasound techniques, 109–112
- Microwave energy, 595
- Middle aortic syndrome, 471, 474–475
- Milk-alkali syndrome, 88, 393, 394
- MIP. *See* Maximum intensity projection (MIP)
- Mixed epithelial and stromal tumors (MEST), 502, 526, 646
- Modification of Diet in Renal Disease Study Group (MDRD), 26, 750, 754, 841
- MRI. *See* Magnetic resonance imaging (MRI)
- MSK. *See* Medullary sponge kidney (MSK)
- Multicystic dysplastic kidney (MCDK), 285, 287–289, 307, 308, 325–329, 579, 689, 690
- Multidetector CT urography (MDCTU)
 calyceal deformities, 60
 CTU, 60
 excretory phase, 60
 indications, 158–160
 radiation dose, 155, 157, 158
 reconstruction algorithms, 154–155
 renal anatomy, 160
 technique, 151–153
- Multilocular cystic nephroma, 93, 182, 308, 579, 646, 647, 698
- Multilocular cystic tumor, 182, 579
- Multiple myeloma, 343, 576, 584, 746, 827, 828
- Myelolipoma, 578
- Myeloperoxidase (MPO), MR imaging, 879–880

- N**
- N*-butyl-cyanoacrylate (NBCA), 196, 197
- Necrosis. *See also* Acute tubular necrosis
 acute renal failure, 741
 childhood urinary tract infection, 683–687
 genitourinary tuberculosis, 439, 440
 parenchymal, 771
 prerenal and renal ARF, 741
 renal medullary and papillary, 346–351
- Neoplasm. *See also* Renal cell neoplasm
 benign tumors, 217
 malignant tumors, 217–219
- Nephrectomy
 distant metastases, 819
 partial
 complications, 819
 surgical method, 819
 tumoral recurrence, 819
 postoperative imaging surveillance, 820
 radical
 complications, 819
 surgical method, 819
 tumoral recurrence, 819
- Nephrocalcinosis
 causes and incidence, 392
 conditions causing, 392
 cortical (*see* Cortical nephrocalcinosis)
 medullary (*see* Medullary nephrocalcinosis)
 parenchymal calcifications, 392, 394
 ultrasound (US)
 appearance, 692
 echogenic papilla, 692
 grading, 693
- Nephrogenic adenoma, 623
- Nephrogenic ridge/cord, 5
- Nephrogenic systemic fibrosis (NSF)
 clinical features, 830–831
 contrast material role, 831–832
 definition, 830
 diagnosis, 832
 guideline, 834
 risk factors, 831
 therapy, 832–834
- Nephrolithiasis
 abdominal radiographs, 399
 calculi types
 calcium oxalate, 397
 cystine stones, 397
 indinavir calculi, 398
 matrix calculi, 398
 oxalate calculi, 398
 struvite/infective calculi, 397
 uric acid calculi, 398
 xanthine calculi, 398
 calculus formation
 clinical and metabolic presentation, 395
 extracorporeal shock wave lithotripsy (ESWL), 395
 principal locations, 395
 ureteric calculi, 395
 computed tomography
 unenhanced CT, 403–406
 urography, 406–407
 incidence and epidemiology
 age, 396
 diet, 397
 environmental factors, 396–397
 inherited diseases, 396
 predisposing factors, 396
 race and sex, 395–396
 socio-economic factors, 397
 intravenous excretory urography, 399–400
 magnetic resonance urography (MRU), 407
 pathophysiology, 397
 prevalence, 398
 ultrasound, 400–402
- Nephrolithotomy, 138, 158, 262, 271–273, 395
- Nephronophthisis (NPHP), 287, 292
- Nephron physiology, 20–23
- Nephron-sparing surgery (NSS)
 complications, 566
 hemostatic agents, 813
 malignant renal tumors in, 573
 postsurgical defect, 811
 small renal tumors, 810
 techniques of, 811
- Nephropathy. *See also* Contrast media-induced nephropathy (CIN)
 allograft, chronic, 250, 757, 780–782
 recurrence, 782
- Nephrosclerosis, 29, 33, 36, 98, 202, 342, 354, 475, 711–716, 724, 726, 727, 741–743, 748, 750, 751, 808
- Neuro-endocrine tumor (NET), 579
- Neurofibromas, 528
- Neurofibromatosis, 14, 201, 205, 471, 474, 526, 528, 532, 698
- Nonvascular interventional radiology
 catheters, 264–265
 complications, 266–268, 271
 CT, 263–264
 fluoroscopy, 262
 guidewires, 264
 indications, 265, 267, 268, 271
 MRI, 264
 needles, 264
 nephrolithotomy, 262
 percutaneous lithotripsy and nephrolithotomy, 271
 percutaneous nephrostomy, 267–268, 271–273
 preparation, 265–268, 271
 suprapubic tube placement, 277–278
 success rate, 266, 268–271
 technical success, 272, 274
 techniques, 266–269
 ultrasonography, 262–263
 ureteral ballooning, 273–274
 ureteral embolization, 274–277
 ureteral stenting, 273
- NPHP. *See* Nephronophthisis (NPHP)
- NSF. *See* Nephrogenic systemic fibrosis (NSF)
- NSS. *See* Nephron-sparing surgery (NSS)
- Nuclear medicine
 blood sampling, 226–227
 clinical applications, 233
 cortical agents, 226
 dynamic renal scintigraphy, 227–229
 glomerular-filtered agents, 224–22
 oncological tracers, 226
 radionuclide cystography, 229–233
 radiopharmaceuticals, 224
 renal cancer, 243–244
 renal failure, 233–235
 renal transplantation, 240–243
 renovascular hypertension, 238–240

- static renal scintigraphy, 229
 - tubular excreted agents, 225–226
 - urinary tract dilatation, 235–238
 - urinary tract infection, 238
- O**
- Obstructive uropathy**
- benign neoplasms, 368
 - congenital anomalies, 362
 - CT urography
 - chronic obstructive uropathy, 359, 727
 - parapyelic cysts, 359
 - ureteropelvic junction obstruction, 358, 360–366, 369, 374, 687, 689–691
 - urinary collecting system dilation, 346, 356, 357, 366, 368
 - definitions, 687–688
 - dynamic diuretic Tc^{99m}MAG3 scintigraphy, 688
 - elderly patients, 72
 - imaging algorithm
 - megaureter, 689–691
 - multicystic dysplastic kidneys (MCDK), 689, 690
 - ureteropelvic junction obstruction, 689, 690
 - imaging findings
 - ultrasound, 355, 356
 - unenhanced spiral CT, 355–356
 - intravenous excretory urography, 356–359
 - MRU, 688, 689
 - excretory MR urography, 360, 361
 - multi-slice technique, 361
 - protocol sequences, 361
 - respiratory imaging and breathold imaging, 359
 - signal-to-noise ratio (SNR), 359
 - single-slice projection, 361
 - static-fluid MR urography, 360, 361, 363, 366, 369, 370, 372, 373, 378, 379
 - nonureteral tumor, 369
 - postsurgical obstruction, 368
 - pregnancy, 368
 - renal pelvis blood clot, 368
 - renal stones
 - acute flank pain, 365–366
 - acute ureteral obstruction, 366, 368, 370
 - chemical composition, 365
 - distal ureteral obstruction, 371, 372
 - horseshoe kidney, 369
 - indirect signs, 365
 - middle ureter obstruction, 373
 - segmental obstruction, 372
 - stone size and location, 365
 - twinkling artifact, 371
 - retroperitoneal fibrosis, 366, 367, 374
 - ultrasound (US)
 - hydronephrosis grading, 354, 356
 - resistive index (RI) assessment, 355, 357
 - unenhanced spiral CT, 355–356
 - ureteral tumors, 368–369, 379, 380
 - ureteropelvic junction obstruction
 - congenital and acquired causes, 363
 - longstanding ureteropelvic junction obstruction, 362, 364
 - pyelocaliectasis, 362, 364
 - segmental, 362, 365
- Oncocytoma**
- baseline and color Doppler US, 518, 520, 521
 - bilateral renal involvement, 523, 527
 - Birt–Hogg–Dubé syndrome, 523
 - characteristics, 518
 - chromophobe carcinoma, 517
 - computed tomography, 521–523
 - diagnosis, 518
 - incidence, 517
 - magnetic resonance imaging, 522–523
 - microscopic features, 517
 - papillary adenomas, 523–524
 - treatment, 517
- Oncological tracers, 226**
- Osteodystrophy, plain radiography, 788, 789, 793**
- Osteosarcoma, 502, 636, 638, 639**
- P**
- Papillary adenomas, 501, 523–524**
- Papillary renal cell carcinoma, 106, 140, 178, 254, 502, 632, 664, 666, 724, 783, 797**
- Papillomas, 368, 623**
- Parapelvic cysts, 306, 308, 312, 314, 315, 355, 359**
- Parapyelic cysts, 71, 358**
- Parenchymal injuries, 484, 488–489, 493, 497**
- Parenchymal necrosis, 771**
- Parietal peritoneum, 75, 77**
- Partial nephrectomy**
- complications, 815–817
 - surgical method, 810–813
 - tumoral recurrence, 819, 821
- PCNL. *See* Percutaneous nephrolithotomy**
- Pediatric kidney**
- acute and chronic renal failure, 703
 - congenital hydronephrosis, 687
 - cystic renal disease, 702
 - imaging and radiation protection issues
 - computed tomography, 676
 - IVU, 676, 677
 - MRU, 676, 679
 - scintigraphy, 676, 679
 - ultrasound (US) appearance, 676, 677
 - VCUG, 676, 678–679
 - neoplasms (*see* Renal neoplasms in childhood)
 - nephrocalcinosis (*see* Nephrocalcinosis)
 - obstructive uropathy (*see* Obstructive uropathy)
 - parenchymal disease, 702–703
 - renovascular disorders
 - congenital variations, 695
 - hemolytic-uremic syndromes, 694–695
 - renal artery stenosis, 694
 - renal vein thrombosis, 694, 695
 - trauma, 703–704
 - urinary tract infection (*see* Childhood urinary tract infection)
 - urolithiasis (*see* Urolithiasis)
 - vesicoureteral reflux (*see* Vesico-ureteral reflux assessment)
- Pediatric urinary tract infection, 683–687**
- Pelvic lymphoma, 784**
- Percutaneous biopsy**
- indications, 253–254
 - technique, 254
- Percutaneous lithotripsy, 271**
- Percutaneous nephrolithotomy (PCNL), 138, 151, 158, 271–273, 395, 406**
- Percutaneous nephrostomy, 19, 143, 261–263, 267–268, 273–275, 453, 470, 587, 607, 689**
- Percutaneous renal mass biopsy, 559**

- Percutaneous transluminal angioplasty (PTA)
 catheters, 195
 premounted balloon, 195
 suboptimal result, 193
- Percutaneous transluminal renal angioplasty (PTRA), 199, 240
- Perinephric abscess. *See* Acute renal infections
- Peripelvic cysts, 306, 312
- Perirenal fibrosis, 367, 448, 586–587
- Persistent nonnephrotic proteinuria, 250
- Phakomatoses
 hemangioma, 528, 531
 neurofibromas, 528, 532
 tuberous sclerosis, 526–527
- Plasmacytoma, 502, 576
- Pneumocystis jirovecii*, 344, 451, 452
- Polyarteritis nodosa (PAN), 337–341, 475, 877
- Polycystic kidney diseases
 ADPKD, 317–321
 ARPKD, 321–322
- Polyvinyl alcohol (PVA), 196, 565
- Positron emission tomography (PET)
 lymph node metastases, 243
 oncological tracers, 226
 oncology, 224, 226
 primary renal tumour, 226
- Postrenal acute renal failure. *See* Acute renal failure (ARF)
- Posttransplant lymphoma, 632
- Pre-clinical molecular imaging
 principles
 magnetic resonance imaging (MRI), 865
 optical imaging (OI), 866
 positron emission tomography (PET), 866–867
 single photon emission tomography (SPECT), 866, 869
 probe, 866
- Prerenal acute renal failure. *See* Acute renal failure (ARF)
- Preservation, grafts, 758
- Pronephros, 6, 11
- Prosthetic bridge graft (PBG), 798–801, 803
- Proteinuria, MR imaging, 882, 884
- Prune belly syndrome, 287, 297, 302, 687, 698
- Pseudotumor. *See* Renal pseudotumor
- Pyelonephritis. *See also* Bacterial pyelonephritis; Emphysematous pyelonephritis; Xanthogranulomatous pyelonephritis (XGP)
 acute right flank pain, 729
 chronic, 88
 diabetic/immunosuppressed patients, 728
- Pyonephrosis. *See also* Pyelonephritis; Renal pyonephrosis
 causes, 374, 375
 clinical presentation, 374–375
 computed tomography, 375
 percutaneous aspiration, 375
 purulent debris, 374
 US examination, 374–375
- R**
- Radiation nephritis, 475–477
- Radical nephrectomy
 complications, 813–817
 surgical method, 808–813
 tumoral recurrence, 817–823
- Radiofrequency ablation
 adjuvant therapy, 596
 biopsy controversy, 596–597
 complications, 599, 600
 vs. cryoablation, 595
- imaging follow-up, 597
 imaging pitfalls, 597–598
 laparoscopic approach, 596, 597
 outcomes for, 598, 599
 patient selection
 laboratory values and biopsy, 594
 pretreatment imaging, 594
 tumor size and location, 594
 percutaneous procedure, 595
 procedure, 595–597
- Radiological anatomy and variants
 anterograde, 52–53
 computed tomography (CT), 30–31
 computed tomography angiography (CTA), 45–46
 conventional radiography, 28
 CT urography, 53
 excretory urography, 52–53
 glomerular filtration rate (GFR), 25–28
 gray-scale and Doppler ultrasound, 28, 29, 45–46
 intravenous excretory urography, 39, 41, 52, 57–60, 66–72
 macroscopic renal anatomy, 17–20
 magnetic resonance imaging (MRI), 31–34
 microscopic renal anatomy, 20–23
 MRA, 46, 47
 MR urography, 53, 56, 57
 multidetector CT urography, 60, 66–72
 nephron physiology, 20–23
 normal renal physiology, 23–25
 pelvic kidney, 42
 renal parenchyma, 28–43
 renal vessels, 43–52
 retrograde pyelography, 52–53
 unilateral renal agenesis, 36
 urinary tract, 52–72
- Radionuclide cystography (RNC), 229, 232, 233, 238, 295, 376, 377, 683
- Radiopharmaceuticals, 223–227, 232, 235, 293, 294, 420, 423, 865
- Randall's plaque, 87–89, 397
- RAVF. *See* Renal arteriovenous fistula (RAVF)
- RCC. *See* Renal cell carcinoma (RCC)
- Reconstruction algorithms, 45, 127, 129, 154–155, 160, 309
- Reflux nephropathy, adults
 calyceal distortions, 376, 385
 causes, 375, 376
 parenchymal alterations, 376
 renal morphology changes, 384
 vesico-ureteral reflux
 grades, 376
 pathophysiology, 375
 voiding sonocystography, 376–378
- Renal agenesis, 12, 13, 36, 285–287, 374, 567, 742
- Renal allograft dysfunction, 249–250
- Renal angiography and vascular interventional radiology
 acute renal ischemia, 209
 arteries, 191–193, 195, 197–201
 arteriovenous fistulas, 212
 atherosclerotic renal artery, 202–205
 benign tumors, 217
 causes, 209
 diagnostic angiography, 190–193
 endovascular interventions, 190, 195–197
 fibromuscular dysplasia (FMD), 190, 204–209
 malignant tumors, 190, 217–219
 renal artery aneurysms, 212
 renal phlebography, 198
 renal transplantation, 216–217

- renal vein thrombosis, 209
- trauma, 190, 194, 209, 212–216
- vascular interventions, 193–197
- veins, 198, 201
- Renal arteriovenous fistula (RAVF), 212, 771, 816
- Renal artery aneurysms, 212, 214, 251, 268, 477–478
- Renal artery stenosis (RAS)
 - clinical criteria, 471
 - Doppler ultrasound, 471–472
 - fibromuscular dysplasia, 472–474
 - middle aortic syndrome, 474–475
 - MRA techniques, 472
 - neurofibromatosis, 474
 - Takayasu's disease, 474, 475
- Renal biopsy
 - acute renal injury, 249
 - chronic kidney injury, 250
 - clinical indications, 248–250
 - complications, 256–257
 - contraindications, 248, 250–251
 - evaluation and division, 253
 - fixatives, 253
 - idiopathic nephrotic syndrome, 247
 - indications, 253–254
 - isolated glomerular hematuria, 250
 - needle types, 252–253
 - persistent nonnephrotic proteinuria, 250
 - renal allograft dysfunction, 249–250
 - site, 252
 - technique, 254
- Renal calculi. *See* Nephrolithiasis
- Renal cancer, 106, 226, 243–244, 253, 507, 542, 546, 549, 550, 554–556, 559, 564, 728, 782, 808, 869
- Renal cell carcinoma (RCC)
 - acquired cystic kidney disease
 - development process, 792
 - diagnosis, 792, 793, 795–798
 - prevalence, 792
 - ADPKD, 316
 - advanced, 217–219
 - angiomyolipoma (AML), 323
 - avascular, 551
 - chromophobe cell type, 551
 - clear cell (*see* Clear cell RCC)
 - collecting duct tumors, 551
 - cryoablation (*see* Cryoablation)
 - dialysis, 316
 - hemangioblastoma, 323
 - hereditary (*see* Hereditary renal carcinoma)
 - histologic subtypes, 538, 545
 - hyperdense renal cyst, 310
 - hypovascular/avascular, 553–554
 - indications, 594
 - medullary type, 553
 - metastases and recurrence, imaging
 - bone, 559
 - dyspnea, 560
 - gallbladder, 558
 - liver, 559, 560, 562
 - lungs, 559
 - pleura, 559, 562
 - multilocular cystic nephroma, 315
 - nephron-sparing surgery, 550–551, 565–567
 - papillary type, 550–551
 - percutaneous biopsy, 559, 568
 - radiofrequency ablation (*see* Radiofrequency ablation)
 - risk factors, 538
 - sarcomatoid type, 553
 - sporadic forms, 323
 - staging
 - American joint committee RCC stage grouping, 557
 - follow-up imaging, 558
 - imaging modalities, 556–558
 - Robson's RCC classification, 557
 - TNM classification, 557
 - transarterial embolization (TAE), 564–565
 - tumor size, 542
- Renal cell neoplasm
 - oncocytomas (*see* Oncocytoma)
 - papillary adenomas, 523–524
 - World Health Organization (WHO) histological classification, 501, 502
- Renal cystic disease
 - acquired cystic kidney disease, 315–317
 - autosomal dominant polycystic kidney disease, 317–321
 - autosomal recessive polycystic kidney disease, 321–322
 - chronic lithium nephropathy, 329–330
 - complex cysts, 310–312
 - diagnostic features, 308
 - extraparenchymal cysts, 312–315
 - kidney disorders, 307
 - localized cystic disease, 315
 - medullary sponge kidney (MSK), 323
 - multicystic dysplastic kidney (MCDK), 325, 327–329
 - simple cysts, 306, 308–310
 - tuberous sclerosis complex, 323
 - von Hippel–Lindau (VHL) disease, 323
- Renal echogenicity, 29, 87–90, 336, 345, 693, 741
- Renal ectopia, 12, 13, 39, 42, 43, 229, 283, 285
- Renal epithelial and stromal tumors (REST), 646
- Renal failure
 - acute renal failure (*see* Acute renal failure (ARF))
 - chronic renal failure (*see* Chronic renal failure)
 - differential diagnosis, 450
 - signs and symptoms, 739
- Renal hypoplasia, 285–287
- Renal infarction, 99, 114, 147, 151, 218, 229, 366, 404, 418, 475, 476, 485, 575, 580, 646, 713, 715, 719–721, 741, 816, 817.
 - See also* Geriatric kidney
- Renal infections. *See also* Geriatric kidney
 - AIDS patients, 451–452
 - cholesteatoma, 451, 464
 - chronic pyelonephritis, 437–439
 - fungal infections (*see* Fungal infections)
 - genitourinary tuberculosis (*see* Genitourinary tuberculosis)
 - malacoplakia (*see* Malacoplakia)
 - renal replacement lipomatosis (*see* Renal replacement lipomatosis (RRL))
 - xanthogranulomatous pyelonephritis (*see* Xanthogranulomatous pyelonephritis (XGP))
- Renal injury
 - AAST grading system, 485
 - complications
 - hypertension, 497
 - persistent urinoma, 497
 - renal cyst rupture, 497
 - computed tomography, 484
 - computed tomography findings (*see also* Catastrophic renal parenchymal injury)
 - contusions, 485, 486, 490
 - hematomas, 488, 493
 - parenchymal injuries, 488, 493

- Renal injury (*cont.*)
- renal infarcts, 486, 491
 - subcapsular hematomas, 485, 487
 - urine leaks, 485–487
 - grading, 485
 - hematuria, 484
 - hemodynamic stability, 484
 - imaging findings and management, 484, 493, 495–497
 - intervention
 - active renal bleeding, 488, 489
 - catastrophic renal injury, 489–495
 - high grade renal injury, 485
 - injury grading, 485–486
 - renal artery stenting, 490
 - urinoma, 486, 488
 - intravenous pyelogram (IVU), 484
 - MDCT grading, 485
 - penetrating renal injuries
 - flank and back injuries, 485
 - parenchymal wounds, 484
 - pedicle injuries, 484
 - renal abnormalities, 495, 496
- Renal lymphoma
- extranodal involvement, 631, 731
 - imaging features and differential diagnosis
 - atypical findings, 635
 - infiltrative disease, 632–634
 - multiple masses, 573, 632–634
 - perirenal disease, 634–635, 731
 - retroperitoneal extension, 633
 - solitary masses, 634, 731
 - imaging modalities
 - computed tomography, 635
 - diagnostic approach, 636
 - magnetic resonance imaging, 635
 - positron emission tomography computed tomography, 635
 - pathogenesis, 632, 636
- Renal masses management
- definition of, 807
 - distant metastases, 817–823
 - percutaneous image-guided biopsy, 808
 - solid masses, 807, 808
 - surgical methods
 - complications, 813–817
 - partial nephrectomy, 810–813, 815–817
 - radical nephrectomy, 809–810, 814–815
 - tumoral recurrence, 817–823
- Renal medullary and papillary necrosis, 346–351
- Renal neoplasms in childhood
- imaging, benign tumors
 - angiomyolipoma, 696, 697
 - lymphangiomatosis, 698
 - mesoblastic nephroma, 696–698
 - metanephric adenoma, 676, 697
 - oncocytoma, 698
 - ossifying renal tumor of infancy, 696, 697
 - renal teratoma, 698
 - reninoma, 697
 - indeterminate renal masses
 - multilocular cystic nephroma, 698
 - nephroblastomatosis, 698–699
 - malignant tumors
 - clear cell sarcoma, 701
 - leukemia, 702
 - lymphoma, 702
 - renal cell carcinoma, 701
 - renal medullary carcinoma, 701
 - Wilms' tumor (nephroblastoma), 699–702
- Renal nephrosclerosis, 29, 33, 98, 342, 711, 715, 724, 726, 727, 741–743, 748, 751, 808
- Renal parenchymal and inflammatory diseases
- anatomical variants, 28–43
 - computed tomography, 30–31
 - conventional radiography, 26
 - diabetic nephropathy, 336, 340–341
 - drug nephropathies, 345
 - glomerulonephritis, 336–340
 - gray-scale and Doppler ultrasound, 28–30, 44–52
 - HIV-associated nephropathy, 344–345
 - hypertension, 321, 322, 327
 - lupus systemic erythematosus, 342, 343
 - magnetic resonance imaging, 31–34
 - metabolic and hematological disease-related nephropathies, 343
 - morphology, 34–36
 - pediatric diseases, 345–346
 - renal medullary and papillary necrosis, 346–351
 - renal vasculitides, 338–340
 - tubulo-interstitial nephritis, 337–338
- Renal phlebography, 198, 201, 209
- Renal pH, MR imaging, 880, 881
- Renal plasma flow (RPF), 224, 225
- Renal pseudotumor
- acquired, 588–589
 - amyloidosis, 584
 - congenital
 - dromedary hump, 588
 - hilar lips, 588
 - prominent (or hypertrophied) column of Bertin, 588
 - splenorenal fusion, 589
 - Erdheim–Chester disease, 586–587
 - extramedullary hematopoiesis, 588
 - hematomas, 584, 585
 - hemorrhagic cysts, 589
 - infection
 - aspergillosis, 582
 - hydatid cyst, 582–583
 - pyelonephritis, 580–583
 - renal tuberculosis, 581–582
 - xanthogranulomatous pyelonephritis, 581
 - inflammatory pseudotumor, 587
 - malacoplakia, 583–584
 - perirenal fibrosis, 586–587
 - sarcoidosis, 584
 - sinus histiocytosis, 584–586
 - sinus lipomatosis, 587–588
 - systemic lupus erythematosus (SLE), 586
 - vascular anomalies, 589
- Renal pyonephrosis, 182, 183, 381–384
- Renal replacement lipomatosis (RRL)
- calculi, 448
 - chronic inflammation, 448
 - staghorn calculus, 448
 - xanthogranulomatous pyelonephritis
 - left kidney, 448, 449
 - right kidney, 450
- Renal rhabdomyosarcoma, 636–638, 696
- Renal sarcoma
- diagnostic approach, 639–642
 - imaging features
 - angiosarcoma, 636, 637
 - chondrosarcoma, 638

- ES-PNET, 638
 - fibrosarcoma, 637
 - granulocytic sarcomas (chloromas), 638–639
 - hemangiopericytoma, 637
 - Kaposi sarcoma, 639
 - leiomyosarcoma, 636–638
 - liposarcoma, 636–637
 - malignant fibrous histiocytoma, 637
 - osteosarcoma, 638–639
 - renal rhabdomyosarcoma, 638
 - renal synovial sarcoma, 638, 641
 - pathogenesis, 636
 - primary and secondary sarcoma, 636
 - Renals cysts
 - tuberous sclerosis complex, 306, 308, 323
 - von Hippel–Lindau disease, 323
 - Renal sinus lipomatosis, 28, 29, 35, 71, 87, 460, 462, 587–588
 - Renal stones. *See* Obstructive uropathy
 - Renal subcapsular hematoma, 99, 485–487
 - Renal synovial sarcoma, 638, 641
 - Renal transplantation, 47, 151, 176, 184, 216–217, 229, 233, 240, 242, 243, 248, 374, 377, 412, 543, 702, 742, 751, 757–784, 787, 789, 792, 793, 874
 - Renal tuberculosis. *See* Genitourinary tuberculosis
 - Renal tumors, 31, 34, 35, 53, 100, 105, 106, 116–118, 133, 137, 138, 140, 181, 209, 218, 251, 254, 255, 263, 264, 495, 504, 508, 516, 519, 523, 538, 540, 542, 543, 553–555, 559, 564, 571, 573–582, 589, 596, 604, 612, 646, 648, 696, 697, 723, 730, 796, 808, 810–812, 817, 819, 821
 - Renal vascular abnormalities
 - arterial disease (*see* Arterial disease)
 - intrarenal arterial disease (*see* Intrarenal arterial disease)
 - venous disease (*see* Venous disease)
 - Renal vasculitides, 337, 338, 340, 341, 740
 - Renal vein thrombosis (RVT), 29, 50, 52, 132, 147, 149, 151, 158, 209, 287, 336, 345, 346, 356, 404, 470, 471, 478, 616, 693–695, 699, 703, 721, 723, 769, 771, 775, 777, 780
 - Renal vessels, 10, 29, 39, 43–52, 83, 92, 94, 97, 98, 100–105, 113, 123, 136, 184, 190, 209, 258, 471, 475, 544, 566, 612, 633, 637, 698, 703, 724, 740, 751, 760, 783, 810, 816, 847
 - Reninoma. *See* Juxtaglomerular cell tumors
 - Renovascular hypertension (RVH), 45, 151, 160, 193, 198, 202, 205, 238–240, 471, 472, 715, 808, 855
 - Retrograde pyelography, 52–53, 158, 451, 604, 607, 609, 610, 612, 618, 621, 622
 - Retroperitoneum
 - anterior and posterior renal fascia, 76–79
 - computed tomography, 76, 77, 79
 - Gerota's fascia, 77
 - peritoneal foldings, 75
 - sagittal plane, 78
 - RNC. *See* Radionuclide cystography (RNC)
 - RPF. *See* Renal plasma flow (RPF)
 - RRL. *See* Renal replacement lipomatosis (RRL)
 - RVH. *See* Renovascular hypertension (RVH)
 - RVT. *See* Renal vein thrombosis (RVT)
- S**
- SAE. *See* Stimulated acoustic emission (SAE)
 - Sarcoidosis, 88, 345, 393, 394, 396, 397, 584
 - Sarcoma. *See* Renal sarcoma
 - Sarcomatoid renal cell carcinoma, 638
 - SCA. *See* Sick cell anemia (SCA)
 - Scleroderma, 475–476
 - SCT. *See* Sick cell trait (SCT)
 - Secondary renal tumors
 - imaging features and differential diagnosis, 572–573
 - liver and renal metastases, 571
 - Sickle cell anemia (SCA), 90, 345, 575, 701
 - Sickle cell trait (SCT), 179, 553, 575, 701
 - Signal-to-noise ratio (SNR), 30, 31, 34, 47, 56, 57, 84, 110, 152, 168, 175, 176, 359–361, 383, 719, 843, 856
 - Simple cysts, 306–310, 315, 318, 320, 503, 531, 539, 664, 667, 798
 - SLE. *See* Systemic lupus erythematosus (SLE)
 - Small angiomyolipoma
 - CT, 504–506, 515
 - MR imaging, 505, 507
 - unenanced and contrast-enhanced US, 504, 506, 507
 - SNR. *See* Signal-to-noise ratio (SNR)
 - Sodium, MRI imaging, 881, 882
 - Solid and cystic renal tumors, 90–97, 105. *See also* Benign solid renal tumors
 - Solid tumors, renal transplantation, 782–783
 - Solitary fibrous tumor, 181, 502, 577–578
 - Static renal scintigraphy, 229–231, 686
 - Stem cell tracking, MR imaging, 876–878
 - Stenosis. *See also* Renal artery stenosis (RAS)
 - renal artery
 - diagnosis, 717, 718
 - multifactorial origin, 768
 - symptoms, 769
 - ureteral, 760, 763–766
 - Stimulated acoustic emission (SAE), 109, 110
 - Struvite calculi, 397, 398
 - Subcapsular hematomas, 99, 209, 485–487, 585
 - Supernumerary renal arteries, 10
 - Suprapubic tube placement, 262, 277–278
 - Systemic kidney diseases
 - diabetic nephropathy, 340–341
 - HIV-associated nephropathy, 344–347
 - hypertension, 340–42, 344, 345
 - lupus systemic erythematosus, 342–343
 - metabolic and hematological disease, nephropathies, 343
 - Systemic lupus erythematosus (SLE), 250, 342–343, 475, 586, 695, 719, 740
- T**
- Takayasu's disease, 205, 471, 474, 475
 - TCC. *See* Transitional cell carcinoma (TCC)
 - ^{99m}Tc-glucoheptonate-dimercaptosuccinic acid (^{99m}Tc-DMSA), 226, 230–233, 238, 239, 242, 284, 285, 287, 288, 295, 297, 420, 423, 681, 685
 - Thrombosis
 - elderly patients
 - causes, 721
 - contrast-enhanced CT, 721–723
 - diagnosis, 723
 - pulmonary emboli, 723
 - unenanced CT, 724
 - transplantation
 - renal artery, 767
 - renal vein, 769–770
 - Transarterial embolization (TAE), 564–565
 - Transitional cell carcinoma (TCC)
 - anterograde pyelography, 607–609
 - computed tomography
 - diffuse infiltration, 618, 619
 - hydronephrosis, 615, 616
 - ultrasound (US), 616, 617, 619

- Transitional cell carcinoma (TCC) (*cont.*)
- differential diagnosis
 - computed tomography features, 622
 - endometriosis, 623
 - nephrogenic adenoma, 623
 - wall thickening and induration, 623
 - elderly, 730
 - follow-up, 622
 - intravenous excretory urography
 - calyceal obliteration, 605
 - discrete filling defects, 605, 607
 - hydronephrosis, 605
 - multiple filling defect, 605
 - oncocalyces, 615
 - polypoid filling defect, 605
 - single filling defect, 605, 607
 - MR imaging
 - advantages, 615
 - cup shaped dilatation, ureter, 615
 - disadvantages, 615
 - hydronephrosis, 615
 - isointense/hyperintense TCC, 612, 615
 - multicentric diffusely infiltrating TCC, 620, 621
 - static or dynamic MR urography, 613, 615
 - multidetector CT urography
 - benign indications, 610
 - diffuse infiltration, right kidney, 618
 - diffusely infiltrating TCC, 610, 620
 - distal ureter, 621
 - excretory urography, 609–611
 - filling defect, 610–612
 - hematuria, 610, 611
 - intravenous urography, 609
 - urothelial neoplasms, 609, 610
 - pathology and histology, 604
 - retrograde pyelography
 - goblet sign, 607
 - ureter dilatation, 607–609
 - TNM staging system, 621–622
 - ultrasonography, 605
- Transplantation
- epidemiology, 757–758
 - long-term follow-up
 - calculus disease, 782
 - chronic allograft nephropathy (CAN), 780–782
 - chronic renal insufficiency (CRI), 782
 - lymphoproliferative disorders, 783
 - solid tumors, 782
 - medical complications
 - clinical considerations, 771–780
 - imaging techniques, 780
 - presurgical evaluations, 758
 - radiological assessment
 - MRI and CT, 762, 763
 - ultrasonography, 760, 761
 - surgical techniques, 758–759
 - urological complications
 - fistulas, 762–763
 - infections, 766
 - perigraft fluid collections, 766–767
 - stenosis, 763–766
 - vascular complications
 - biopsy, 771
 - infarctions, 767–768
 - parenchymal necrosis, 771
 - renal artery stenosis (RAS), 768–769
 - renal artery thrombosis, 767
 - renal vein thrombosis, 769–771
- Trauma. *See* Renal injury
- Tuberous sclerosis (TS), 254, 292, 306–308, 323, 324, 504, 505, 511, 523, 526, 530, 538, 539, 554, 556, 697, 698
- Tubule dysfunction, MR imaging, 578
- Tubulocystic carcinoma, 648, 649
- Tumoural antigen targeting
 - small animal-MRI (SA-MRI), stem cells tracking, 864–869
 - small animal-PET (SA-PET)
 - renal cell carcinoma evaluation, 866, 867
 - renal function analysis, 866–867
- U**
- Ultrasonography, 132, 202, 209, 216, 235, 249, 262–264, 284, 287–290, 292–295, 297, 299, 318, 322, 329, 415, 420, 423, 429, 501, 573, 579, 605, 645, 649, 650, 758, 760, 761, 764
- Ultrasound (US)
 - clinical applications, 107, 113–119
 - contrast-specific, 107–112
 - Doppler technique, 85, 92–98
 - dynamic phases, 112–113
 - insonation power, 109
 - microbubble artifacts, 112–113
 - microbubble contrast agents, chemical composition, 107–108
 - normal anatomy, 85–87, 92–98
 - renal echogenicity, 87–90
 - renal ultrasound examination, 105–107
 - safety, 108–109
 - solid and cystic renal tumors, 90–92
 - technology, 83–85
- Upper urinary tract
 - adenocarcinoma, 623
 - benign tumors
 - giant fibroepithelial polyp, 623, 628
 - papillomas, 623
 - epidermoid carcinoma, 62, 622
 - undifferentiated carcinoma, 623
- Upper urinary tract tumors. *See* Transitional cell carcinoma (TCC)
- Uremia. *See* Uremic syndrome
- Uremic syndrome
 - acquired cystic kidney disease (ACKD)
 - characteristics, 792
 - renal cell carcinoma, 792, 793, 796, 797
 - dialysis access complications
 - arteriovenous fistula, 798–800
 - arteriovenous grafts, 800–803
 - catheters, 803–805
 - vascular stenoses, 798
 - electrolyte alterations, 788
 - extrarenal disorders
 - cardiovascular complications, 788
 - chronic renal failure, 788, 789, 791, 792
 - musculoskeletal abnormalities, 789
 - neurologic complications, 789
 - vascular calcifications, 789
- Ureteral embolization, 262, 274–277
- Ureteral stenting
 - complications, 273
 - indications, 273
 - preparation, 273
 - success rate, 273
 - techniques, 273

- Ureteral stones, 105, 357, 365, 395, 401, 403, 404, 610, 616, 692.
See also Obstructive uropathy
- Ureteric calculi. *See* Nephrolithiasis
- Uretero-pelvic junction injury, 495
- Uric acid calculi, 162, 398
- Urinary tract dilatation, 57, 60, 107, 176, 182, 229, 233, 235–238, 297, 359, 368, 383, 404, 743, 745
- Urinary tract infection, 43, 151, 158, 233, 238, 251, 273, 278, 293–295, 310, 354, 365, 366, 374, 375, 377, 395, 397, 412, 437, 451, 464, 480, 583, 584, 615, 620, 622, 623, 680, 682–687
- Urinary tract obstruction. *See also* Obstructive uropathy
 clinical manifestations, 353, 354
 hydronephrosis, 354–356
 location, 361, 362, 365
 morphologic manifestation, 354
 obstructive uropathy (*see* Obstructive uropathy)
 partial obstruction, 354
 pyonephrosis (*see* Pyonephrosis)
 reflux nephropathy (*see* Reflux nephropathy, adults)
 renal damage, 354, 355
- Urine leaks, 278, 485–489, 494
- Urolithiasis
 IVU, 692
 twinkling sign in, 392
 ultrasound (US) appearance, 692
 urinary stones, 692
- USPIO particles, 186, 875
- V**
- Varicocele formation, 479
- Vascular abnormalities. *See* Renal vascular abnormalities
- Vascular interventions, 193–195, 831
- VCUG. *See* Voiding cystourethrography (VCUG)
- Venous disease
 gonadal vein thrombosis, 479
 lymphangiomatosis, 479
 renal vein thrombosis (RVT), 478
 varicocele formation, 479
- Vesico-ureteral reflux assessment
 grading of, 682, 683
 imaging algorithm, 683
 radionuclide cystography (RNC), 683
 ultrasound
 scarred kidney, 682
 urothelial sign, 680
 voiding cystourethrography (VCUG), 682–683
- Voiding cystourethrography (VCUG)
 double moiety, 236, 239
 renal damage, 238
 vesicoureteral reflux, 232, 233
- von Hippel–Lindau disease (VHL), 106, 254, 323, 325, 326, 523, 538, 554, 555, 594, 664, 698, 701, 811. *See also* Hereditary renal carcinoma
- W**
- Walf body, 6
- Wegener’s granulomatosis, 475, 589
- Wilms tumor, 11, 14, 43, 526, 575, 577, 580, 696–702, 811
- Wilson’s disease, 393, 394
- X**
- Xanthine calculi, 398
- Xanthogranulomatous pyelonephritis, 179, 182, 445–448, 458–460, 481, 583, 612, 623, 634, 684, 685, 693
- Xanthogranulomatous pyelonephritis (XGP)
 computed tomography
 extrarenal diffusion and gas component, 459
 finer calcifications, 448
 spherical low-density non enhancing areas, 445
 focal form, 448
 intravenous excretory urography (IVU), 445, 447
 manifestation, 445
 multifocal enlargement, 445
 perirenal space, 448
 stages, 445